Compounds > 4,6-dihydroxypyrimidine
Page last updated: 2024-11-05

4,6-dihydroxypyrimidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

4,6-Dihydroxypyrimidine, also known as uracil, is a pyrimidine base that is a fundamental component of RNA. It plays a crucial role in the synthesis of proteins and other biological processes. Uracil is formed through the deamination of cytosine, and its presence in RNA is essential for the recognition and binding of amino acids during protein synthesis. The synthesis of uracil involves the enzymatic conversion of orotic acid to uridine monophosphate (UMP), which is further phosphorylated to form UDP and UTP. Uracil is also involved in the regulation of gene expression and the immune response. Research on uracil focuses on its role in various biological processes, its potential therapeutic applications, and its implications in disease pathogenesis.'

Cross-References

ID SourceID
PubMed CID14512
CHEMBL ID1722176
CHEBI ID184008
SCHEMBL ID152294
SCHEMBL ID8088423

Synonyms (60)

Synonym
6-hydroxy-3,4-dihydropyrimidin-4-one
EN300-25578
BB 0242395
4(3h)-pyrimidinone, 6-hydroxy-
4,6-dihydroxypyrimidine ,
nsc22838
nsc-22838
1193-24-4
4(1h)-pyrimidinone, 6-hydroxy-
4,6-pyrimidinediol
nsc 22838
einecs 214-772-3
4,6-dihydroxypyrimidin [german]
6-hydroxy-1h-pyrimidin-4-one
pyrimidine-4,6-diol
4,6-dihydroxypyrimidine, 98%
AB-323/25048196
smr000368133
MLS000774924
6-hydroxy-4(1h)-pyrimidinone
AC-2511
inchi=1/c4h4n2o2/c7-3-1-4(8)6-2-5-3/h1-2h,(h2,5,6,7,8)
dufgycaxviuxip-uhfffaoysa-
6-hydroxy-3h-pyrimidin-4-one
D1821
CHEBI:184008
4-hydroxy-1h-pyrimidin-6-one
AKOS003237466
STL139315
STL135950
NCGC00246132-01
HMS2744P17
AKOS005746727
6-hydroxypyrimidin-4(3h)-one
6-hydroxy-4-pyrimidinone
unii-6l93v0s662
4,6-dihydroxypyrimidin
ec 214-772-3
6l93v0s662 ,
FT-0617255
PS-3433
AM20080136
hydroxy-4(1h)-pyrimidinone, 6-
SCHEMBL152294
SCHEMBL8088423
mfcd00016733
SY001718
4,6-dihydroxy pyrimidine
CHEMBL1722176
STR03284
W-108518
DTXSID6025434
F0176-0211
6-hydroxy-4(3h)-pyrimidone
CS-W016618
BCP00979
Q27265097
SB57283
HY-W015902
Z56766633
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxypyrimidine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.46 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index34.82 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510